11 Ovarian Cancer Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Ovarian Cancer Studies in New Haven

NCT06161025Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer....

New Haven, CTPHASE2860 participantsDaiichi Sankyo

View Study Details

NCT06824467Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevaciz...

New Haven, CTPHASE3770 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06843447Recruiting

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickl...

New Haven, CTPHASE1460 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06072781Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progr...

New Haven, CTPHASE3270 participantsVerastem, Inc.

View Study Details

NCT06234423Recruiting

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors....

New Haven, CTPHASE1263 participantsOnCusp Therapeutics, Inc.

View Study Details

NCT06690775Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer....

New Haven, CTPHASE2230 participantsTORL Biotherapeutics, LLC

View Study Details

NCT05659381Recruiting

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Reg...

New Haven, CTPHASE3220 participantsGOG Foundation

View Study Details

NCT05761561Recruiting

Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

An anticipated 200 women with newly diagnosed ovarian and endometrial cancer scheduled to receive chemotherapy (adjuvant chemotherapy after surgery or neoadjuvant chemotherapy before surgery) will be ...

New Haven, CTNA200 participantsYale University

View Study Details

NCT06890338Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuxim...

New Haven, CTPHASE2140 participantsAbbVie

View Study Details

NCT07226427Recruiting

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 mono...

New Haven, CTPHASE1100 participantsStemline Therapeutics, Inc.

View Study Details

NCT06315491Recruiting

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 1...

New Haven, CTPHASE240 participantsCybrexa Therapeutics

View Study Details

About Ovarian Cancer Clinical Trials in New Haven

Ovarian cancer originates in the ovaries or fallopian tubes and is often called a "silent killer" due to subtle early symptoms. It is the fifth leading cause of cancer death among women. Treatment typically involves surgery and chemotherapy, with newer targeted therapies showing promise.

There are currently 11 ovarian cancer clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 3,553 participants. Research is being sponsored by Daiichi Sankyo, Merck Sharp & Dohme LLC, Verastem, Inc. and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ovarian Cancer Clinical Trials in New Haven — FAQ

Are there ovarian cancer clinical trials in New Haven?

Yes, there are 11 ovarian cancer clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What ovarian cancer treatments are being tested?

The 11 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for ovarian cancer.

Data updated July 17, 2026 from ClinicalTrials.gov